Dr. Walter Greenleaf is a neuroscientist and medical technology developer at Stanford University. With over 35 years of research and product development experience, he is considered a leading authority on digital healthcare applications. He was the Director of the Mind Division at the Stanford Center on Longevity, where he focused on age-related changes in cognition. Walter was the founding Chief Science Officer for Pear Therapeutics, a pioneering company in SaMD. He also served as CEO of Virtually Better, a company that develops virtual environments for the treatment of phobias, anxiety disorders, and PTSD. Walter’s current focus is on designing, developing, and validating clinical systems that leverage biosensing, AI, and XR technology to address challenging problems in behavioral and physical medicine, such as cognitive aging, post-traumatic stress, anxiety disorders, depression, traumatic brain injury and stroke, addictions, and autism spectrum disorder. Walter is the Research & Innovations Director for the Stanford Medical Mixed Reality Center. He is also an advisor to the Stanford Virtual Human Interaction Lab, the Stanford Wearable Electronics (eWear) Program, and the Stanford Virtual Reality & Immersive Technology (VR-IT) Clinic. He currently advises Interaxon as Chief Science Officer and is the Board Chair for the International Virtual Reality Health Association (IVRHA). To see the video version of this podcast go to https://youtu.be/9viM-_w08x4.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related